Hina Ogawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hina Ogawa has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ayumi Ishiwatari
Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
1 shared publication - Chise Sugita
Department of Pulmonary Medicine, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
1 shared publication - Fumihiko Yasui
Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
1 shared publication - Hiroko Beppu
Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
1 shared publication - Hitomi Kimura
Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
1 shared publication - Kaori Kojima
Department of Nephrology, Tokyo Metropolitan Health and Hospitals Corporation Okubo Hospital, Tokyo, Japan
1 shared publication
Latest Publications
- 6 September 2021
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (2) , 170-177
Hemodialysis patients with coronavirus disease 2019: reduced antibody response
Background Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD. Methods SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients. Results After propensity score matching, the median levels of IgG-S1 in the HD patients at 7–13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7–13 days compared with non-severe patients. Conclusion COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.
- 6 September 2021
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 26 (2) , 170-177
Hemodialysis patients with coronavirus disease 2019: reduced antibody response
Background Because patients on maintenance hemodialysis (HD) have an impaired immune response to pathogens, they are at higher risk of severe coronavirus disease 2019 (COVID-19). However, data on antibody production among HD patients with COVID-19 is scarce. Thus, we performed a retrospective cohort study evaluating severe acute respiratory syndrome coronavirus two antibody (SARS-CoV-2) production within 1 month after COVID-19 onset in hospitalized patients on HD. Methods SARS-CoV-2-specific immunoglobulin (Ig) G levels were quantified using an iFlash 3000 Chemiluminescence Immunoassay analyzer (Shenzhen YHLO Biotech Co., Ltd.) to detect IgG antibodies specific for the S1 subunit of the spike protein (IgG-S1). Propensity score matching was used to balance covariate distribution in HD and non-HD patients. From April 2020 to February 2021, antibody testing was performed on 161 hospitalized patients with symptomatic COVID-19. Of them, 34 HD patients were matched to 68 non-HD patients. Results After propensity score matching, the median levels of IgG-S1 in the HD patients at 7–13 days after symptom onset were significantly lower than in non-HD patients, especially in those with severe disease. Among all patients, those with severe disease produced lower levels of IgG-S1 at 7–13 days compared with non-severe patients. Conclusion COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.